The Ets transcription factor, Fli-1, has been shown to play a pivotal role in the induction and progression of Friend Murine Leukemia Virus (F-MuLV)-induced erythroleukemia, with its overexpression leading to erythroblast survival, proliferation, and inhibition of terminal differentiation. P53 inactivation is an additional genetic alteration that occurs in late-stage leukemic progression associated with in vivo and in vitro immortalization. Since p53 protein expression levels are low, to undetectable, in primary erythroleukemic cells that express elevated levels of Fli-1, we investigated the potential regulation of p53 by Fli-1. We assessed whether the overexpression of Fli-1 could partially regulate p53 via modulation of its wellestablished regulator, MDM2. In this paper, we demonstrate that the promoter of MDM2 contains a consensus binding site for Fli-1 that is bound by this transcription factor in vitro and in vivo, resulting in MDM2 transcriptional regulation. We further substantiate these observations in vivo by demonstrating a positive correlation in the expression of Fli-1 and MDM2, and a negative correlation with p53 in leukemic tissues obtained from mice with Friend Disease. These observations depict a significant function of Fli-1 overexpression in the indirect control of p53, evidently capable of leading to an increasingly aggressive erythroleukemic clone in vivo. Oncogene (2005) 24, 962-969.
Introduction
During the progression of leukemia, hematopoietic progenitors acquire the ability to evade both differentiation, by uncontrolled proliferation in the absence of appropriate growth signals, and apoptosis, leading to refractory disease. Several of the genetic mutations mediating these altered cellular events have been well studied in the murine model of Friend Disease. In this model, newborn mice infected with Friend Murine Leukemia Virus (F-MuLV) develop a multistage erythroleukemia manifested by splenomegaly and anemia (Silver and Kozak, 1986 ; reviewed in Lee et al., 2003) . The virus itself does not contain any oncogenic sequences, but the integration of the proviral DNA into the host genome of erythroid progenitors is sufficient to induce the characteristic erythroleukemia. Using this murine model, our laboratory has demonstrated that in leukemias induced by F-MuLV, the pivotal genetic event associated with disease initiation is the insertional activation of the Fli-1 gene (Ben-David et al., 1990) . Fli-1 belongs to the Ets family of transcription factors, many of which have been associated with oncogenesis, including human malignancies (reviewed in Oikawa and Yamada, 2003) .
The clinical relevance of Fli-1 is highlighted in the pediatric disease, Ewing's sarcoma, in which an aberrant transcription factor is created as a result of a chromosomal translocation, resulting in a fusion product between the EWS and Fli-1 genes (Delattre et al., 1992) . The putative role of Fli-1 in human disease is not restricted to Ewing's sarcoma. A potential role for Fli-1 in systemic lupus erythematosus was previously proposed (Zhang et al., 1995) , in which elevated levels of Fli-1 mRNA were detected in the lymphocytes of patients affected with this disease. More recently, Fli-1 has been shown to be negatively regulated by another Ets transcription factor, Tel (Lopez et al., 1999) . Through a direct protein-protein interaction with Fli-1, Tel inhibits the transactivation capacity of Fli-1, thereby preventing regulation of Fli-1 target genes. It has therefore been proposed that in leukemias where Tel is involved in chromosomal translocations, the regulation of Fli-1 is no longer maintained, allowing for improper modulation of its target genes. In this way, Fli-1 contribution to human disease may be greater than previously anticipated.
Studies utilizing erythroleukemia cell lines have implicated the overexpression of Fli-1 with deregulated erythropoiesis. The ectopic expression of Fli-1 results in the inhibition of erythroid differentiation (Pereira et al., 1999; Tamir et al., 1999) , perhaps through a modulation of signals emanating from the erythropoietin receptor (Zochodne et al., 2000) . The relevance of Fli-1 during in vivo erythropoeisis is further supported by the generation of Fli-1-deficient mice, in which a reduction in hematopoietic progenitors, including BFU-E and CFU-E, has been observed in knockout embryonic livers (Kawada et al., 2001) . As a transcription factor, the oncogenic effects of Fli-1 are primarily mediated by the transcriptional modulation of its target genes. Not surprisingly, Fli-1 has been reported to regulate an array of genetic targets, many of which have been implicated in carcinogenesis. These studies reveal the ability of Fli-1 to function as both a repressor and activator of transcription. Among others, Fli-1 has been reported to regulate the expression of genes such as Rb and Bcl-2, whose roles in malignancy have been well established (Tamir et al., 1999; Lesault et al., 2002) . Thus, by these and other yet unidentified means, the pivotal role of Fli-1 in Friend erythroleukemia and in human malignancies becomes apparent.
In addition to Fli-1 insertional activation, another critical molecular event in the progression of Friend Disease is the inactivation of the p53 tumor suppressor. Studies examining the genetic requirements for immortalization of erythroleukemic cells in culture demonstrate the necessity of acquiring p53 mutations in this model (Howard et al., 1993) . Moreover, p53
À/À mice infected with F-MuLV exhibit accelerated disease, suggesting that the loss of p53 function is crucial for leukemic transformation (Wong et al., 1999) . Hence, p53 deficiency accelerates Friend Disease as its loss results in the inhibition of apoptosis as well as the induction of genomic instability, thereby the acquisition of mutations required for immortalization (Wong et al., 1999) .
Initially cloned as a spontaneously amplified gene leading to cellular transformation, the MDM2 oncoprotein has since been shown to be a critical regulator of the p53 tumor suppressor (Momand et al., 1992) . By virtue of its E3 ubiquitin ligase activity, MDM2 is able to target p53 for proteosomal degradation, thereby playing a pivotal role in modulating cellular levels of p53 (Fang et al., 2000) . Furthermore, MDM2 provides an additional level of regulation through direct binding to p53, resulting in the inhibition of p53 transactivating potential. The role of MDM2 in transformation, however, is not restricted to p53 regulation. There is growing evidence that MDM2 may contribute to malignancy through its involvement in other cellular pathways.
In this report, we are the first demonstrate that Fli-1 is able to recognize and bind to an Ets consensus sequence present in the promoter of MDM2, resulting in its upregulation both in vitro and in vivo. This binding results in the transcriptional activation of this oncoprotein both in established cell lines and during in vivo progression. This suggests that as an oncogene, Fli-1 not only is effective in blocking differentiation, promoting proliferation and increasing cell survival, but also serves to attenuate the p53-mediating by upregulating MDM2. This attenuation is pivotal for initial erythroid transformation by increasing genomic instability to potentiate further genetic alterations.
Results

MDM2 promoter contains an Ets site recognized and bound by Fli-1 in vitro
Members of the Ets family of transcription factors recognize a purine-rich consensus sequence found in the promoters of their target genes. An examination of the MDM2 promoter reveals the presence of two Ets sites, one of which is a consensus site recognized by Fli-1 (CCGGAAGC) (Rao et al., 1993; Mao et al., 1994) . Ries et al. (2000) highlighted the significance of the region of the promoter containing this Ets site, as removal of this site greatly abolished MDM2 promoter activity (Ries et al., 2000) . To verify whether Fli-1 is able to recognize this sequence in the MDM2 promoter, oligonucleotides spanning the Fli-1 consensus sequence in the MDM2 promoter were incubated with bacterially expressed GST-Fli-1 in an electromobility shift assay (EMSA). As a positive control, the E74 sequence, which was previously shown to be recognized by Fli-1, was used. As shown in Figure 1 , Fli-1 bound to the synthetic MDM2 oligonucleotides, forming a complex that retarded migration in the gel. The specificity of this association was demonstrated by using 100-fold excess of the cold oligonucleotides to compete with the radioactively labeled oligonucleotides in the binding reaction. These results demonstrate that Fli-1 specifically recognizes the Ets consensus sequence of the MDM2 promoter and is able to form a protein-DNA interaction in vitro.
To assess the relevance of this interaction in a more biological context, we examined whether Fli-1 could recognize and bind to the MDM2 promoter in vivo. This interaction was therefore analysed in erythroleukemia cell lines by means of a chromatin immunoprecipitation assay (ChIP). The cell lines used were HB60-5 cells, which express relatively low levels of Fli-1, and CB3 cells that express high levels of Fli-1 as a result of F-MuLV integration. As a control, 293T cells, which do not express Fli-1 levels detectable by Western analysis, were also used. The Fli-1 levels of these cell lines are depicted in Figure 2a . Following crosslinking of the proteins to the DNA, the chromatin from these cells was isolated, and subjected to immunoprecipitation using a Fli-1 antibody. The bound DNA was then analysed by PCR specifically amplifying a 193 bp region corresponding to the MDM2 promoter. Our results demonstrate that in both HB60-5 and CB3 cells, the Fli-1 antibody can precipitate chromatin containing the MDM2 promoter, generating the expected 193 bp PCR product, which was also detected in the CB3 genomic DNA reaction (positive control). As expected, no PCR product was detected in reactions using 293T cells, nor in immunoprecipitations in which an unrelated antibody to COX-2 was used as a negative control (Figure 2b ). These results provide evidence for the in vivo binding of Fli-1 to the MDM2 promoter, suggesting a potential regulatory role for Fli-1 in transcription of the MDM2 gene.
Transactivation of the MDM2 promoter by Fli-1
As both a repressor and an activator of transcription, Fli-1 has been shown to regulate a number of target genes associated with cellular transformation. Previously identified transcriptional targets include Rb and Bcl-2 (Tamir et al., 1999; Lesault et al., 2002) . To investigate whether Fli-1 has the ability to modulate the expression of MDM2, a known negative regulator of p53, we used two MDM2 luciferase constructs ; L1 (full length) and L3 (deleted Ets A site). Coexpression of Fli-1 in 293T cells with the reporter construct resulted in a dose respond increase in reporter activity compared to the vector control ( Figure 3a) . Such increase in reporter activity is associated with dose response increase in level of Fli-1 in transfected cells (Figure 3b ). In depth analysis of the MDM2 promoter by Ries et al. (2000) demonstrated that independent of p53 transcriptional regulation, the MDM2 promoter could be transactivated by the ras pathway. In these studies, a dominant active form of Raf was shown to activate the MDM2 promoter (Ries et al., 2000) . We have previously implicated Fli-1 in the signaling events downstream of the Epo receptor, and have shown that ectopic expression of Fli-1 in the erythroblastic cell line HB60-5 results in the activation of the ras pathway in response to erythropoietin stimulation (Zochodne et al., 2000) . In the parental cell line, ras activation was not detected during Epo-induced erythroid differentiation. To eliminate the possibility that the upregulation observed by Fli-1 was due to increased activation of the ras/Raf/MAPK pathway, we used the MEK inhibitor PD90859 in the luciferase assays using 293T cells. Ectopic expression of Fli-1 in nonerythroid 293T cells is not expected to activate the ras pathway ( Figure 3c ). Indeed, the inhibition of MAPK activation by PD90859 had no effect on the ability of Fli-1 to transactivate the MDM2 promoter, demonstrating a ras-independent regulation of the MDM2 promoter by Fli-1.
In order to assess whether the activation of the ras/raf/ MAPK pathway resulted in MDM2 upregulation in our cell model, we generated HB60-5 cells overexpressing a dominant active form of ras. A comparison of MDM2 protein levels between the vector control and HB60-ras cells revealed a significant increase in the cells overexpressing the dominant active ras, as shown in Figure 4 . These results are concordant with the work of Ries et al. (2000) , demonstrating that in our erythroid cell model, MDM2 is downstream of the ras/raf/MAPK pathway as well. Furthermore, our findings reveal that Fli-1 is downstream of the ras pathway (unpublished results), and as such may act as a downstream effector. However, the regulation seen in our luciferase assays ( Figure 3a) is independent of ras activation as the vector and Fli-1 transfectants presumably possess equal ras-activating capabilities as the same cells were used in the experiments.
Ectopic Fli-1 expression increases MDM2 levels in HB60-5 erythroleukemic cells
The regulation of gene expression by Fli-1 has proven to alter a number of pathways involved in leukemogenesis, Figure 1 DNA-binding activity of recombinant Fli-1 protein to a consensus sequence in the MDM2 promoter. Lysates of bacterial cells expressing GST-Fli-1, or GST, were incubated with radioactively labeled oligonucleotides designed from the MDM2 promoter. Binding was tested in the presence of the nonspecific competitor poly(dI-dC) and in the presence of 100-fold excess cold competitor DNA. As a positive control, the E74 sequence was used. The samples were resolved on a 5% polyacrylamide gel Figure 2 In vivo binding of Fli-1 to the MDM2 promoter. A ChIP assay was performed to demonstrate the in vivo association of Fli-1 with the MDM2 promoter. The levels of Fli-1 protein in each of the cell lines used were determined by Western Blot analysis (a). The association was detected in HB60-5 and CB3 cells, but not in 293T cells, which express low to undetectable protein levels of Fli-1 (b). Negative controls include a DNA-free reaction, and immunoprecipitation with an irrelevant antibody against COX-2. Genomic DNA obtained from CB3 cells was used as a positive control including cellular proliferation, inhibition of erythroid differentiation, and cell survival. As a nuclear effector, Fli-1 achieves these cellular modifications by modulating the expression of its target genes. To investigate the possibility that Fli-1 may modulate the expression of the potent oncogene, MDM2, we used a retroviral vector to overexpress Fli-1 in HB60-5 cells. As shown in Figure 5a and b, the ectopic expression of Fli-1 in this cell line lead to increased RNA and protein levels of MDM2. The increased upregulation of MDM2 by Fli-1 did not correlated with upregulation of endogenous p53 (Figure 5c ). These results demonstrate that Fli-1 is able to modulate transcriptional activation of MDM2 in vivo.
Fli-1 expression correlates with MDM2 expression in vivo within spleen A mutation in p53 is a critical event in the establishment of murine erythroleukemic cell lines. Sequencing of the p53 gene of HB60-5 cells revealed a mutant version of the gene, while in the CB3 cell line, the p53 gene was deleted. Thus, to investigate such regulation in vivo, the biological relevance of this upregulation was further examined in the spleens of infected mice with primary disease compared to the healthy controls as presented below. It is known that primary transformed blasts express wild-type p53, while still hyperproliferate in spleen of infected mice (Tamir et al., 1999) . To assess whether the increased expression of Fli-1 has an impact on the levels of MDM2 and subsequently inducing instability of wild-type p53 in the hematopoietic component of the spleen, newborn mice were infected and the disease was allowed to progress to term. After 8 weeks, mice were killed and the spleens were excised. Western Blot analyses using protein lysates extracted from infected and noninfected splenic tissues were performed. As shown in Figure 6 , higher levels of Fli-1 protein expression were detected in the leukemic spleens compared to the healthy controls. The increased expression of Fli-1 correlated with elevated levels of MDM2, providing supporting evidence for in vivo regulation by Fli-1. Further analyses revealed a concomitant decrease in p53 levels in mice exhibiting leukemic phenotypes, supporting the notion of MDM2 transcriptional regulation by Fli-1 in vivo.
Discussion
Since its initial discovery, the oncogenic potential of Fli-1 has become increasingly evident. Early studies investigating the putative role of Fli-1 in malignant transformation have been primarily focused on the ability of this transcription factor to inhibit erythroid differentiation. However, emerging data suggest a more comprehensive role for Fli-1 in leukemic progression, with its increasing list of transcriptional targets and potential protein-protein interactions. Since one of the critical genetic events leading to erythroleukemia induced by F-MuLV is the insertional activation of Fli-1, it is not surprising that this transcriptional regulator possesses the ability to alter and disrupt a number of cellular pathways and processes. For instance, we have previously demonstrated that Fli-1 is a direct transcriptional repressor of the retinoblastoma gene, Rb. As such, the downregulation of Rb contributes to the erythroleukemic phenotype potential of erythroblasts, as it affects not only cell cycle progression but also inhibits erythroid differentiation (Tamir et al., 1999) . Fli-1 has more recently been shown to activate transcription of the Bcl-2 gene (Lesault et al., 2002) . In this way, the Fli-1 oncogene contributes to cell survival, as the upregulation of Bcl-2 results in the evasion of the normal apoptotic program. In the present study, we have presented evidence to suggest the direct transcriptional regulation of MDM2 by Fli-1, both in erythroleukemic cells and in mice infected with F-MuLV, providing an additional function for Fli-1 during leukemic progression.
Earlier studies have delineated a significant role for the p53 tumor suppressor during malignant transformation in erythroleukemia and the acquisition of p53 mutation is believed to be one of the critical steps during disease progression. These mutations have been reported to include retroviral insertion within the p53 gene itself, as well as deletion or point mutations (Ben-David et al., 1988) . We have previously investigated the temporal order of the genetic events during Friend Disease progression, and observed that Fli-1 rearrangement and consequent upregulation was the first detectable genetic alteration, followed by the acquisition of mutations within the p53 gene. However, almost all of the p53 mutations could only be detected in cell lines that have been serially transplanted into syngeneic mice, presumably to allow for the acquisition of further mutations (Howard et al., 1993) . Interestingly, infection of p53 À/À mice with both FV-P and F-MuLV strains of Friend virus resulted in accelerated disease progression (Prasher et al., 2001) . These results raise the possibility that Fli-1 activation in primary erythroleukemic cells Figure 6 Correlation between Fli-1 and MDM2 levels in splenic tissues derived from erythroleukemic versus healthy mice. Protein was extracted from spleens isolated from healthy and erythroleukemic mice. Western analysis was performed to determine the levels of Fli-1 and MDM2, as well as the levels of p53. As a loading control, b-actin was used. Lanes 1-3 represent lysates obtained from healthy, noninfected mice, and lanes 4-6 represent lysates from spleens of mice infected with F-MuLV (8 weeks postinfection) may function to inhibit the tumor suppressor function of p53 until further genetic alterations are achieved. In addition to its conventional role as a tumor suppressor by exhibiting the ability to control malignant cell expansion by G1 arrest or induction of apoptosis, p53 has more recently been implicated in the differentiation process of hematopoietic cells, including those of the erythroid lineage (Chylicki et al., 2000) . As such, it is reasonable to assume that the negative regulation of p53 by Fli-1 would provide a selective advantage to the proliferating leukemic erythroblasts, by gaining a proliferative capacity, yet losing the capability to differentiate. Furthermore, p53 and Rb have been reported to act cooperatively as tumor suppressors (Xu et al., 1996; Cordon-Cardo et al., 1997) , suggesting that the suppression of both Rb and p53 by Fli-1 would further select for an aggressive erythroleukemic clone.
The direct upregulation of MDM2 and the consequential downregulation of p53 by Fli-1 support the notion that Fli-1 possesses the traits of a bona fide oncogene, and through the regulation of its target genes provides the erythroblasts with the necessary genetic alterations to become fully transformed. Although it may appear that Fli-1 may have a redundant function in the suppression of p53 by MDM2, it is conceivable that during early oncogenic transformation, Fli-1 may serve to maintain elevated levels of MDM2 in order to further attenuate the tumor suppressor function of p53, prior to p53 acquiring genetic mutations at a later stage of the disease. We have shown such a response both in vivo and in vitro by the use of murine splenic tissues obtained from F-MuLV-infected mice. This is consistent with our initial findings showing the upregulation of MDM2 by Fli-1 resulting in the downregulation of p53 protein in HB60-Fli-1 cells. This downregulation of p53 is likely mediated by increased MDM2 levels, as Northern analyses revealed that while levels of MDM2 mRNA increased in Fli-1-overexpressing cells, levels of p53 mRNA remained unchanged (unpublished results). Hence, these results are consistent with the low, to undetectable levels of p53 protein expression in the majority of the primary erythroleukemic cells (Howard et al., 1996) .
As we have previously shown that the induction of erythroleukemia by F-MuLV is accelerated in p53-deficient mice, it is likely that reduced levels of p53 confer an in vivo selective advantage during leukemogenesis. While primary erythroleukemic cells within the spleen express elevated levels of Fli-1 and MDM2, the in vitro luciferase assays only show approximately a twofold increase following transfection with Fli-1. The increase in MDM2 levels in the leukemic spleens compared to the age-matched, healthy spleens in our in vivo data, which appear to be more significant than our in vitro results, may be suggestive of additional indirect pathways that may serve to activate MDM2 in order to suppress p53 activity. This observed difference may be, at least in part, a consequence of Fli-1 regulating other pathways that also regulate MDM2. This would be concordant with results reported by Ries et al. (2000) , in which they demonstrate that MDM2 is transactivated downstream of ras activation (Ries et al., 2000) . Their work suggests that MDM2 is regulated in part by Ets factors, as removal of the Ets-binding domain in the MDM2 promoter resulted in a significant decrease in transcriptional activation. Since Fli-1 has been shown to activate the ras pathway through alterations of signal transduction pathways downstream of the Epo receptor, it is therefore possible that ras regulates a number of different Ets factors that may serve to regulate MDM2 levels, perhaps in a cooperative manner. Indeed, in our cell culture model, ras activation also resulted in increases in MDM2 levels, as seen in HB60-ras cells, which overexpress a dominant active form of ras.
While high levels of MDM2 are detected in primary erythroleukemias with Fli-1 activation, p53 mutations are only detected in established erythroleukemia cell lines. The late-stage mutations or deletions in p53 in erythroleukemic cells may seem redundant as elevated MDM2 levels appear to be keeping p53 protein levels low. However, one possibility could be that while low levels of p53 confer an in vivo selective advantage to the erythroleukemic cells, complete loss of this tumor suppressor gene may be required to confer immortalization. The presence of low levels of p53 still present may be sufficient to prevent the erythroleukemic cells from proliferating in culture. However, complete loss of p53, which has been shown to occur in vivo in a limited number of erythroleukemic cells (Howard et al., 1996) , may result in the alteration of additional genetic changes required for immortalization. We have recently demonstrated that Bcl-2 upregulation precedes p53 mutations during F-MuLV-induced erythroleukemia progression. Thus, another possibility that could explain the late inactivation of p53 could be that both Bcl-2 and p53 have overlapping functions in the inhibition of apoptosis. While such overlapping functions confer an in vivo selective growth advantage to erythroleukemic cells, a subsequent loss of p53 is most often required to overcome cellular events to allow for in vitro proliferation.
In addition to the evident selective advantage, the loss of p53 would contribute to Friend Disease, such as increases in genomic instability and decreased apoptosis, the loss or downregulation of p53 may impact the differentiation capacity of erythroblasts. In previous reports, exogenous expression of a wild-type, but not mutated p53 resulted in differentiation of erythroid and myeloid cells (Chylicki et al., 2000) . Therefore, the increased MDM2 expression conferred by Fli-1 overexpression may, in this way, contribute to the inhibition of erythroid differentiation and could, on its own, render erythroid progenitors tumorigenic.
Interestingly, the functional significance of Fli-1 in the megakaryocytic lineage is currently being elucidated. Like many other hematopoeitic transcription factors, Fli-1 appears to play a role in the fate determination of myeloid progenitor cells. In experiments conducted using human erythroleukemia K562 cells, the overexpression of Fli-1 has been shown to result in megakaryocytic differentiation, whereas treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) induced these cells to undergo erythroid terminal differentiation. Of interest is a recent study conducted by Datta and Long, 2002 demonstrating that MDM2 levels were increased in human erythroleukemic cells that had been induced to undergo megakaryocytic differentiation by the addition of phorbol-diesters. This raises the possibility that Fli-1 may also be upregulated in these cells and hence may partially contribute to MDM2 transactivation in this megakaryocytic differentiation model.
In addition to the apparent selective advantage that MDM2 would confer to erythroleukemic cells, there is increasing evidence for a p53-independent function of MDM2. MDM2 has been shown to interact with the retinoblastoma protein (Rb) and E2F1 and may, through these interactions, affect cell cycle progression in a p53-independent manner. A comparison of MDM2 transgenic mice and p53 À/À mice has revealed those overexpressing MDM2 possessing a greater propensity for spontaneous sarcomas (McDonnell et al., 1999) , suggesting that MDM2 possesses p53-independent oncogenic properties. Furthermore, studies have shown that patients with tumors exhibiting both mutations in p53, as well as amplification, and/or overexpression of MDM2 exhibit a poorer prognosis than those with defects in only one of these genes (Cordon-Cardo et al., 1997) . Finally, a role for MDM2 has been reported in hematological malignancies, as it has been found to be overexpressed (but not amplified) in selective leukemias and lymphomas (Watanabe et al., 1996) .
We have shown in the present study, for the first time, that Fli-1 has the capacity to bind to the MDM2 promoter, which results in its increase in expression levels and that these data strongly correlate with our in vivo analysis. This suggests a putative role for MDM2 in malignant transformation during the progression of Friend Disease. The aberrant expression of Fli-1 has been implicated in a growing number of diseases, including human Ewing's Sarcoma, systemic lupus erythematosus, and possibly leukemias in which the Ets factor, Tel, is involved. The identification of additional genes regulated by Fli-1, including MDM2, should contribute to our understanding of the function of this transcription factor in these diseases.
Materials and methods
Cell lines
The CB3 and HB60-5 cell lines were derived from F-MuLVinfected mice. CB3 and 293T cells were maintained in a minimum essential medium supplemented with 10% fetal bovine serum (FBS). For HB60-5 and NKH23 cells, the same medium was supplemented with 1 U of erythropoietin (Epo) (Janssen-Ortho Inc.) and 100 pg of stem cell factor (SCF) per ml (R&D Systems).
RNA extraction and Northern blotting
Total RNA was extracted from cultured cells by using the TRIzol reagent according to the manufacturer's protocol (GIBCO). In all, 20 mg of RNA was dissolved in 2.2 M formaldehyde, denatured at 651C for 15 min and separated by electrophoresis in a 1% agarose gel containing 0.66 M formaldehyde. Following transfer to Zetaprobe membranes, the filters were hybridized with radioactively labeled probe (2 Â 10 6 c.p.m./ml of a-32 P-dCTP)
EMSA
Bacterially expressed GST-Fli-1 protein was used as previously described (Tamir et al., 1999) . The sequences of the sense strands of the oligonucleotides used in the assay were 5 0 -AAT AACCGGAAGTAACTC-3 0 (E74) and 5 0 -TGCGGCTTCCG GGACGGG-3 0 (MDM2). Single-stranded oligonucleotides were radioactively labeled at the 5 0 end by T4 polynucleotide kinase (New England Biolabs) and [g- 32 P]ATP. The singlestranded oligonucleotides were purified using NUCTrap probe purification columns (Stratagene), and annealed to twofold excess cold complimentary oligonucleotides by boiling for 2 min and cooling at room temperature for 1 h. For the binding reaction, 3 ml of GST-Fli-1, or GST alone, were incubated for 30 min at room temperature after the addition of binding buffer (20 mM HEPES (pH 7.9), 1 mM EDTA, 70 mM KCl, 6 mM MgCl 2 , 1 mM dithiothreitol, 10% glycerol), 1 mg of poly (dI-dC), and 0.5 ng of labeled oligonucleotide probes. For competition assays, 100-fold excess cold single-stranded oligos was added to GST-Fli-1 prior to the binding reaction. Samples were run on a 5% polyacrylamide gel in 0.25 Â TBE buffer at 120 V, the gel was dried for 3 h at 601C, and exposed to film.
ChIP assay
CB3, HB60-5, and 293T cells were fixed in 1% formaldehyde for 15 min at 371C and washed twice in PBS containing protease inhibitors. The cells were then lysed in 50 mM Tris-Cl, 10 mM EDTA, 1% SDS, and protease inhibitors. The chromatin was sheared by sonication, generating fragments ranging from 200 to 2000 bp, as verified by agarose gel electrophoresis. Chromatin was isolated as previously described (Andrews and Faller, 1991) . The lysates were precleared by incubation of protein A-sepharose slurry for 45 min at 41C, followed by overnight incubation with 2 mg of the Fli-1 antibody (Santa Cruz), or irrelevant cyclooxygenase-2 (COX-2) antibody (Santa Cruz). Following this incubation, 120 ml of a 20% protein A-sepharose slurry was added for 1 h and lysates were centrifuged for 10 min at 14 000 r.p.m. at 41C. The complexes were washed in 10 mM Tris-HCl pH 8.0, 1% Triton X-100, 0.1% SDS, 2 mM EDTA, 250 mM NaCl, followed by a wash in 10 mM Tris-HCl pH 8.0, 1% Triton X-100, 0.1% SDS, 2 mM EDTA, and 500 mM NaCl, and then in 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 1% NP40, 1% sodium deoxycholate, 0.25 M LiCl, followed by two washes in TE. The complexes were dissociated by adding 250 ml of 0.1 M NaHCO 3 /1% SDS and incubating at room temperature for 15 min. To reverse crosslinks, NaCl was added to the eluates and incubated at 651C for 4 h, followed by 1 h incubation at 451C with 5 mg of proteinase K. DNA was extracted using phenol/chloroform and precipitated with ethanol. PCR was performed using the recovered DNA. The primers used to amplify the MDM2 promoter were GGTCCAGGAGGTG ACAGGT (forward) and ACGGGGCAGCGTTTAAATA (reverse).
Western blotting and antibodies
Cells were harvested and lysed using RIPA buffer (0.5% NP-40, 50 mM Tris HCl (pH 8.0), 120 mM NaCl, 50 mM NaF, 10 mg/ml aprotinin, 100 mg/ml leupeptin, and 10 mM PMSF). Following quantification, 20 mg of total protein lysates were electrophoresed in a 10% acrylamide gel and transferred by using a semidry transfer cell (Bio-Rad) to a PDVF membrane (Millipore). Membranes were blocked in 5% milk, incubated with primary antibodies for 1 h at room temperature, washed and incubated for 1 h with the appropriate HRP-conjugate secondary antibodies. The blots were washed in PBS-T and ECL (Pierce) was used prior to autoradiography. The antibodies used were: Fli-1 polyclonal (Santa Cruz), MDM-2 polyclonal (Santa Cruz), p53-specific monoclonal pAb 240, and b-actin (Sigma) to determine equal loading.
Luciferase reporter assay
Transient transfections into 293T cells were performed using 1 mg of reporter construct, pcDNA 3.0 vector, and pcDNA3-Fli-1 (in indicated concentrations), and 0.5 mg of b-gal. ESCORT transfection reagent (Sigma) was used as described in the manufacturer's protocol. The luciferase reporter constructs used were a generous gift from Dr Frank McCormick, and the L1 (full length) and L3 (deleted EtsA site) constructs have been previously described (Ries et al., 2000) . Transfections were performed in triplicates and repeated a minimum of four times. After 48 h, luciferase activity was measured using (luciferase kit, Promega), as specified by the manufacturer. For assays requiring MAPK pathway inhibition, PD90859 (an MEK inhibitor, Biomol) was added at a concentration of 50 mM to the culture media. Luciferase readings were assessed using a Lumat luminometer. To account for transfection efficiency, b-gal concentrations were used to normalize results.
Tumor isolation from F-MuLV-infected mice
Briefly, BALB/c neonates (n ¼ 3) were infected with Friend Virus (F-MuLV helper virus) 1-day post birth as to induce Friend Disease. Age-matched, noninfected littermates (n ¼ 3) served as controls. After 9 weeks, leukemic mice with palpable spleens and decreased hematocrit values, both measured to ascertain leukemic burden, that is, volume expansion, were sampled. At this point in time, the spleen is highly enriched for leukemic erythroblasts (90%). Mice were anaesthetized with 4% isoflurane and spleens were excised and placed in sterile 1 Â phosphate-buffered saline (PBS), followed by mechanical disruption using a mortar and pestle and washes in 1 Â PBS (2 Â ). Cells were then suspended in RIPA lysis buffer (0.5% NP-40, 50 mM Tris HCl (pH 8.0), 120 mM NaCl, 50 mM NaF, 10 mg/ml aprotinin, 100 mg/ml leupeptin, and 10 mM PMSF). Western blot analysis was then conducted on lysates according to aforementioned methods.
